Document Thérapie 2007 Novembre-Décembre; 62 (6): 473-476
DOI: 10.2515/therapie:2007078
Neuroprotection: Present and future
Régis Bordet1, Pierre Lestage2 and Brigitte Onteniente31 EA1046-Département de Pharmacologie Médicale, Institut de Médecine Prédictive et de Recherche Thérapeutique, Faculté de Médecine de l'Université Lille 2 & Centre Hospitalier et Universitaire de Lille, Lille, France
2 Institut de Recherche Servier, Croissy, France
3 INSERM U549, Université René Descartes Paris V, Paris, France
(Received 12 September 2007; accepted 30 November 2007; published online 4 March 2008)
Abstract - The treatment of brain diseases (regardless of the latter's neurological or psychiatric expression) is based on either preventive, symptomatic or etiopathogenic approaches. The frequent observation of neuronal death during brain disease initially prompted researchers to favour neuroprotection for the etiopathogenic approach. The repeated failure to develop reliable neuroprotective agents has prompted emergence of the concept of "disease modifyer". The disease modifyer concept (based essentially on clinical endpoints) enables us to envisage the broader application of etiopathogenic treatments by freeing ourselves of the need to demonstrate a cellular mechanism of action. The formalization of disease modification prompts several lines of thought, which are developed in the present article.
Key words: neuroprotection -- methodology -- neurodegenerative disease -- mental health disease -- stroke -- clinical trial
© Société Française de Pharmacologie et de Thérapeutique 2008